PDF herunterladen
Facial Plast Surg 2011; 27(6): 517-522
DOI: 10.1055/s-0031-1298784
© Thieme Medical Publishers

Neuromodulators: Available Agents, Physiology, and Anatomy

Kartik Nettar1 , Corey Maas1
  • 1Aesthetic and Facial Plastic Surgery Unit, The Maas Clinic, San Francisco, California
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
28. Dezember 2011 (online)

    Lizenzen und Reprints

ABSTRACT

Neuromodulators have risen to the forefront of aesthetic medicine. By reversibly relaxing target muscles, neuromodulators exhibit their effect by softening hyperfunctional lines. An understanding of their physiology, relevant facial anatomy, and current agents is imperative for a successful aesthetic practice.

KEYWORDS

Botulinum toxin - neuromodulator - Botox® Cosmetic - Dysport®

REFERENCES

  • 1 Simpson L L. The origin, structure, and pharmacological activity of botulinum toxin.  Pharmacol Rev. 1981;  33 155-188
    Google Scholar
  • 2 Rossetto O, Seveso M, Caccin P, Schiavo G, Montecucco C. Tetanus and botulinum neurotoxins: turning bad guys into good by research.  Toxicon. 2001;  39 27-41
    Google Scholar
  • 3 Ahn M S, Catten M, Maas C S. Temporal brow lift using botulinum toxin A.  Plast Reconstr Surg. 2000;  105 1129-1135 discussion 1136-1139
    Google Scholar
  • 4 Maas C S, Kim E J. Temporal brow lift using botulinum toxin A: an update.  Plast Reconstr Surg. 2003;  112 (5, Suppl) 109S-112S discussion 113S-114S
    Google Scholar
  • 5 Janfaza P, Cheney M L. Superficial structures of the face, head, and parotid region. In: Janfaza P, Nadol J B, Galla R J, et al, eds. Surgical Anatomy of the Head and Neck. Philadelphia: Lippincott Williams and Wilkins; 2000: 1-48
    Google Scholar
  • 6 Loos B M, Maas C S. Relevant anatomy for botulinum toxin facial rejuvenation.  Facial Plast Surg Clin North Am. 2003;  11 439-443
    Google Scholar
  • 7 Carruthers J, Fagien S, Matarasso S L. Botox Consensus Group . Consensus recommendations of the use of botulinum toxin type A in facial aesthetics.  Plast Reconstr Surg. 2004;  114 13s-19s
    Google Scholar
  • 8 Matarasso A, Matarasso S L, Brandt F S, Bellman B. Botulinum A exotoxin for the management of platysma bands.  Plast Reconstr Surg. 1999;  103 645-652 discussion 653-655
    Google Scholar
  • 9 Alam M, Dover J S, Klein A W, Arndt K A. Botulinum a exotoxin for hyperfunctional facial lines: where not to inject.  Arch Dermatol. 2002;  138 1180-1185
    Google Scholar
  • 10 Northington M E, Huang C C. Dry eyes and superficial punctate keratitis: a complication of treatment of glabelar dynamic rhytides with botulinum exotoxin A.  Dermatol Surg. 2004;  30 (12 Pt 2) 1515-1517
    Google Scholar
  • 11 Aristodemou P, Watt L, Baldwin C, Hugkulstone C. Diplopia associated with the cosmetic use of botulinum toxin a for facial rejuvenation.  Ophthal Plast Reconstr Surg. 2006;  22 134-136
    Google Scholar
  • 12 Ramirez A L, Reeck J, Maas C S. Preliminary experience with botulinum toxin type B in hyperkinetic facial lines.  Plast Reconstr Surg. 2002;  109 2154-2155
    Google Scholar
  • 13 Ramirez A L, Reeck J, Maas C S. Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines.  Otolaryngol Head Neck Surg. 2002;  126 459-467
    Google Scholar
  • 14 Moy R, Maas C, Monheit G, Huber M B. Reloxin Investigational Group . Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines.  Arch Facial Plast Surg. 2009;  11 77-83
    Google Scholar
  • 15 Monheit G, Carruthers A, Brandt F, Rand R. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose.  Dermatol Surg. 2007;  33 (1 Spec No.) S51-S59
    Google Scholar
  • 16 Brin M F, Blitzer A. Botulinum toxin: dangerous terminology errors.  J R Soc Med. 1993;  86 493-494
    Google Scholar
  • 17 Pickett A M, Hambleton P. Dose standardisation of botulinum toxin.  Lancet. 1994;  344 474-475
    Google Scholar
  • 18 Hambleton P, Pickett A M. Potency equivalence of botulinum toxin preparations.  J R Soc Med. 1994;  87 719
    Google Scholar
  • 19 Marion M H, Sheehy M, Sangla S, Soulayrol S. Dose standardisation of botulinum toxin.  J Neurol Neurosurg Psychiatry. 1995;  59 102-103
    Google Scholar
  • 20 Ascher B, Rzany B J, Grover R. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study.  Dermatol Surg. 2009;  35 1478-1486
    Google Scholar
  • 21 Dressler D. Routine use of Xeomin in patients previously treated with Botox: long term results.  Eur J Neurol. 2009;  16 (Suppl 2) 2-5
    Google Scholar
  • 22 Jankovic J. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm.  Eur J Neurol. 2009;  16 (Suppl 2) 14-18
    Google Scholar
  • 23 Dressler D. Comparing Botox and Xeomin for axillar hyperhidrosis.  J Neural Transm. 2010;  117 317-319
    Google Scholar
  • 24 Benecke R. Xeomin in the treatment of cervical dystonia.  Eur J Neurol. 2009;  16 (Suppl 2) 6-10
    Google Scholar
  • 25 Frevert J. Xeomin: an innovative new botulinum toxin type A.  Eur J Neurol. 2009;  16 (Suppl 2) 11-13
    Google Scholar

Kartik Nettar

Aesthetic and Facial Plastic Surgery Unit, The Maas Clinic

2400 Clay Street, San Francisco, CA 94115

eMail: Drnettar@maasclinic.com

      >